We are live on ! Find out more
BCTX icon

BriaCell Therapeutics

19 hedge funds and large institutions have $1.64M invested in BriaCell Therapeutics in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 19 → 19 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1.19% less ownership

Funds ownership: 5.59% → 4.4% (-1.2%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

69% less capital inflows, than outflows

Capital inflows: $152K | Capital outflows: $499K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
2
Reduced
4
Closed
4
Calls
$29​K
Puts
–
Net Calls
+$29​K
Net Calls Change
+$7​K

BCTX Hedge Fund Activity: Q3 2026 in Review

19 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics (BCTX) for Q3 2026, worth a combined $1.64M — up 3.8% from $1.58M a quarter earlier.

Fund positioning in BCTX was balanced in Q3 2026: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 4 trimmed.

The largest buyer was Tripletail Wealth Management, opening a new position worth an estimated $111K. The largest seller was Sabby Management, exiting entirely with an estimated $262K sold.

  • 19 institutional investors held BriaCell Therapeutics (BCTX) as of Q3 2026, unchanged from Q2 2026.
  • Funds reported $1.64M of BriaCell Therapeutics stock for Q3 2026, up 3.8% quarter-over-quarter.
  • 4 funds opened new BriaCell Therapeutics positions in Q3 2026 and 4 closed out, a net change of 0 holders.
  • The largest BriaCell Therapeutics buyer in Q3 2026 was Tripletail Wealth Management, an estimated $111K added.
  • The largest BriaCell Therapeutics seller in Q3 2026 was Sabby Management, an estimated $262K sold.

Based on aggregated 13F filings for Q3 2026.